Clinical Trials - HALO

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT0668908552 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismRECRUITINGPHASE32025-02-052027-122027-10
NCT03267940Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaTERMINATEDPHASE12017-10-022019-11-112019-11-11
NCT02715804A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaTERMINATEDPHASE32016-03-142019-11-042019-11-04
NCT02563548A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsCOMPLETEDPHASE12015-10-222019-03-262019-03-26
NCT02346370A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLCTERMINATEDPHASE12015-02-102016-11-142016-08-09
NCT03662334A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)COMPLETEDPHASE42013-10-032014-02-272014-02-27
NCT01839487PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerCOMPLETEDPHASE22013-05-142018-09-262018-05-01
NCT01848990CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)COMPLETEDPHASE42013-032014-092014-02
NCT01572012Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy VolunteersCOMPLETEDPHASE12012-022013-112013-11
NCT01526733Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human HyaluronidaseCOMPLETEDPHASE42011-122013-092012-08
NCT01453153Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic CancerCOMPLETEDPHASE1, PHASE22011-092015-052014-02
NCT01275131Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)COMPLETEDPHASE12011-012011-122011-12
NCT01194245Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusCOMPLETEDPHASE22010-082011-082011-08
NCT01194258Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusCOMPLETEDPHASE22010-082011-082011-08
NCT01170897Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid TumorsCOMPLETEDPHASE12010-072014-012013-10
NCT00979875A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs AloneCOMPLETEDPHASE12009-092010-052010-02
NCT00916357Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)COMPLETEDPHASE22009-072009-112009-11
NCT00928447Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact DermatitisCOMPLETEDPHASE22009-06-232009-09-132009-09-13
NCT00883558Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes MellitusCOMPLETEDPHASE22009-052010-042010-02
NCT00862849Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro AloneCOMPLETEDPHASE12009-032009-082009-06
NCT00834704Safety Study of PEGPH20 Given to Patients With Advanced Solid TumorsCOMPLETEDPHASE12009-022012-112012-06
NCT00807963Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate AloneCOMPLETEDPHASE12008-122009-09-212009-09-21
NCT00803972Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20COMPLETEDPHASE12008-112009-08-282009-08-28
NCT00774800Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes MellitusCOMPLETEDPHASE22008-102009-032009-03
NCT00773175Subcutaneous Rehydration Compared to Intravenous RehydrationCOMPLETEDPHASE42008-102009-122009-11
NCT00782587Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder CancerCOMPLETEDPHASE12008-102009-082009-03
NCT00705536Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20COMPLETEDPHASE12007-122008-022008-02
NCT00656370Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)COMPLETEDPHASE42007-122008-01-302008-01-30
NCT00435604A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human HyaluronidaseCOMPLETEDPHASE12007-022007-05
NCT00369187Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human HyaluronidaseCOMPLETEDPHASE42006-072006-10
NCT00318643Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerCOMPLETEDPHASE1, PHASE22006-03-302009-08-112009-08-11
NCT00593281INFUSE Morphine StudyCOMPLETEDPHASE32006-012006-102006-10
NCT00311519A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer SubjectsCOMPLETEDPHASE42005-112006-01